Website Under Maintenance

Newsroom Published Jun 08, 2024 01:50 PM

Our site is down for scheduled maintenance. We are working to update our network to better provide the page you requested. We understand the inconvenience this may cause, but rest assured, we are doing everything we can to bring the site back online after our necessary updates.

Anaptys Announces Participation in March Investor Conferences

By: AnaptysBio, Inc. via GlobeNewswire

February 27, 2025 at 16:15 PM EST

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

TD Cowen 45^th Annual Healthcare Conference, Boston, MA

Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Mar. 4, 2025 at 1:10pm ET / 10:10am PT

Leerink Partners 2025 Global Healthcare Conference, Miami, FL

Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Mar. 11, 2025 at 10:40am ET / 7:40am PT

Barclays 27^th Annual Global Healthcare Conference, Miami, FL

Format – Presentation and one-on-one investor meetings
Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT

Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.

About Anaptys

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com

Website Under Maintenance

Website Under Maintenance

Anaptys Announces Participation in March Investor Conferences

More News